Photodynamic Therapy Clinical Trial
Official title:
Investigation the Clinical Effectiveness of Combination Topical Aminolaevulinic Acid-Photodynamic Therapy With Hydrogel Dressing for Treatment Chronic Cutaneous Wounds
NCT number | NCT06445699 |
Other study ID # | RYin |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2023 |
Est. completion date | June 2024 |
63 patients with chronic infectious wounds were enrolled in the controlled study. They were randomly divided into three groups equally. Group 1 (Grp.1): The patients received hydrogel dressing change at three days intervals. Group 2 (Grp.2): The patients received ALA-PDT treatment at ten days intervals for 4 sessions. Groups 3 (Grp.3): The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals. The wound healing rate, total effective rate, patient satisfaction, adverse reaction, and recurrence were assessed in all groups.
Status | Recruiting |
Enrollment | 69 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - 1) patients with chronic wounds caused by trauma or surgery who failed to heal after traditional formal medical treatment at least over three months; - 2) Patients with stable vital signs who had no systemic medical disease and did not take glucocorticoids, immunosuppressive agents, or anticoagulants during the entire treatment process; - 3) Participants provided signed informed consent, were able to comply with the program, were willing to participate in follow-up, and were able to cooperate in the observation of adverse events and efficacy; - 4) The diameter of the skin wound should not exceed 10 centimeters. Exclusion Criteria: - 1) Patients are allergic to ALA; - 2) Women with recent fertility, pregnancy or lactation plans; - 3) Patients with deepening wounds or worsening infections; - 4) Poor compliance leading to an inability to complete the treatment in its entirety; - 5) Cutaneous ulcer caused by vascular disease, autoimmune diseases, metabolic diseases, local or metastatic malignant tumors. |
Country | Name | City | State |
---|---|---|---|
China | Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University) | Chongqing | Chongqing |
Lead Sponsor | Collaborator |
---|---|
Army Medical University, China |
China,
Khorsandi K, Hosseinzadeh R, Esfahani H, Zandsalimi K, Shahidi FK, Abrahamse H. Accelerating skin regeneration and wound healing by controlled ROS from photodynamic treatment. Inflamm Regen. 2022 Oct 4;42(1):40. doi: 10.1186/s41232-022-00226-6. — View Citation
Morley S, Griffiths J, Philips G, Moseley H, O'Grady C, Mellish K, Lankester CL, Faris B, Young RJ, Brown SB, Rhodes LE. Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobial therapy. Br J Dermatol. 2013 Mar;168(3):617-24. doi: 10.1111/bjd.12098. Epub 2013 Jan 18. — View Citation
Nesi-Reis V, Lera-Nonose DSSL, Oyama J, Silva-Lalucci MPP, Demarchi IG, Aristides SMA, Teixeira JJV, Silveira TGV, Lonardoni MVC. Contribution of photodynamic therapy in wound healing: A systematic review. Photodiagnosis Photodyn Ther. 2018 Mar;21:294-305. doi: 10.1016/j.pdpdt.2017.12.015. Epub 2017 Dec 28. — View Citation
Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020 Jul;21(7):363-383. doi: 10.1038/s41580-020-0230-3. Epub 2020 Mar 30. — View Citation
Xu Y, Chen H, Fang Y, Wu J. Hydrogel Combined with Phototherapy in Wound Healing. Adv Healthc Mater. 2022 Aug;11(16):e2200494. doi: 10.1002/adhm.202200494. Epub 2022 Jul 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse effects | The severity (absent; mild; moderate; severe) and duration of adverse reactions such as pain, burning sensation, erythema, oedema and pigmentation, treatment measures and efficacy were meticulously documented at each treatment and follow-up. | Up to 12 weeks after the end of the treatment. | |
Other | Recurrence | Patients were surveyed about the recurrence after 12 weeks following the final course of treatment. | Up to 12 weeks after the end of the treatment. | |
Primary | Wound healing rate | Panoramic photographs of the wounds were taken by the same observer at each treatment and return visit using a digital camera, and the wound area was recorded using Image-Pro Plus 6.0 software. Wound size on the first day of treatment was considered to be 100%. The change in wound area size was compared to the initial before treatment and calculated as a percentage reduction. | Up to 12 weeks after the end of the treatment. | |
Primary | The total effectiveness rate | The evaluation criteria were as follows: 1) If the wound area is completely healed, treatment was considered "significantly effective" (SE); 2) if the wound area was at least 50% healed, treatment was considered "effective" (E); 3) If the wound area was healed 30 - 50%, the treatment is considered as "improved" (IMP); 4) If the wound area is healed less than 30%, it is considered as "ineffective" (INE). "The total effectiveness rate" (Et) was calculated from the equation as follows:
Et = (NSE+NE)/Nt × 100% NSE = the number of patients belonging to the SE groups NE = the number of patients belonging to the E groups Nt = the total number of patients |
Up to 12 weeks after the end of the treatment. | |
Primary | Patient satisfaction | Patients were surveyed about their level of satisfaction with the results after 12 weeks following the final course of treatment with the results as "satisfied," "somewhat satisfied," "somewhat dissatisfied," or "dissatisfied." | Up to 12 weeks after the end of the treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052033 -
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
|
N/A | |
Recruiting |
NCT05031923 -
Treatment of Intrabony Defects With Simvastatin and Antimicrobial Photodynamic Therapy
|
N/A | |
Completed |
NCT04037709 -
Photodynamic Therapy in Patients With Gingivitis
|
N/A | |
Recruiting |
NCT05043935 -
The Effect of Leukocyte and Platelet-rich Fibrin With Antimicrobial Photodynamic Therapy in Aggressive Periodontitis
|
N/A | |
Not yet recruiting |
NCT06437288 -
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
|
Phase 2 | |
Completed |
NCT01756313 -
Optimizing Uptake of Methylaminolevulinat With Fractional Ablative Laser Technique
|
Phase 4 | |
Withdrawn |
NCT03960125 -
Photodynamic Therapy and Microvesicles
|
Early Phase 1 | |
Recruiting |
NCT01349361 -
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
|
Phase 2 | |
Not yet recruiting |
NCT06468540 -
Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
|
||
Recruiting |
NCT05688904 -
The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
|
Phase 1 | |
Completed |
NCT04037475 -
Treatment of Herpes Labialis by Photodynamic Therapy
|
N/A | |
Recruiting |
NCT04689243 -
Low Concentration ALA-PDT in Treatment of Skin Ulcer
|
N/A | |
Recruiting |
NCT06311890 -
Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne
|
Phase 2 | |
Enrolling by invitation |
NCT05820750 -
Clinical and Radiographic Evaluation of Photodynamic Therapy for Root Canal Treatment of Primary Molars
|
N/A | |
Enrolling by invitation |
NCT04223570 -
Portable Measurement of Protoporphyrin IX in the Skin
|
||
Completed |
NCT03643744 -
Photodynamic Therapy-Induced Immune Modulation: Part III
|
Phase 1 |